Calpeptin

Calpeptin inhibits the Ca²⁺-stimulatedcleavage of p35 to p25 by calpain. It regulates the processing of β-amyloidprecursor protein to β-amyloid (Aβ). Calpeptin alleviates neurite elongation indifferentiating PC12 cells. In platelets, it prevents Ca²⁺-ionophore-induceddegradation of actin binding protein and P235. It blocks the myosinlight chain phosphorylation in platelets stimulated by collagen, ionomycin, orthrombin. Calpeptin inhibits the growth of estrogen receptor positive breast cancer cells. Calpeptin is a cell permeable calpain blocker. It also blocks theactivation of T-cells in the immune system. It has been observed that calpeptininduces secondary inflammatory responses and apoptosis in muscle cells.

Cell permeable: yes

ID50 = 52 nM for calpain-1; 34 nM for calpain-2; 138 nM for papain

Product does not compete with ATP.

Reversible: no

Packaged under inert gas

Toxicity: Standard Handling (A)

Z-Leu-Nle-CHO

Dissolve in a minimal amount of DMF or DMSO then add H₂O, buffer or medium just prior to use.

Lee, M.S., et al. 2000. Nature405, 360.
Yamazaki, T., et al. 1997. Biochemistry27, 8377.
Klafki, H., et al. 1996. J. Biol. Chem.271, 28655.
Shiba, E., et al. 1996. Anticancer Res. 16, 773.
Pinter, M., et al. 1994. Neurosci. Lett. 170, 91.
Saito, K., and Nixon, R.A. 1993. Neurochem. Res. 18, 231.
Tsujinaka, T., et al. 1988. Biochem. Biophys. Res. Commun.153, 1201.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany